Electrographic flow-guided ablation in redo patients with persistent atrial fibrillation (FLOW-AF): design and rationale
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F23%3A00009684" target="_blank" >RIV/00023884:_____/23:00009684 - isvavai.cz</a>
Result on the web
<a href="https://pubmed.ncbi.nlm.nih.gov/37361617/" target="_blank" >https://pubmed.ncbi.nlm.nih.gov/37361617/</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.hroo.2023.04.001" target="_blank" >10.1016/j.hroo.2023.04.001</a>
Alternative languages
Result language
angličtina
Original language name
Electrographic flow-guided ablation in redo patients with persistent atrial fibrillation (FLOW-AF): design and rationale
Original language description
BACKGROUND Electrographic flow (EGF) mapping enables the dy-namic detection of functional or active atrial fibrillation (AF) sour-ces outside the pulmonary veins (PVs), and the presence or absence of these sources offers a novel framework for classifying and treat-ing persistent AF patients based on the underlying pathophysiology of their AF disease.OBJECTIVE The primary objective of the FLOW-AF trial is to eval-uate the reliability of the EGF algorithm technology (Ablamap soft-ware) to identify AF sources and guide ablation therapy in patients with persistent AF.METHODS The FLOW-AF trial (NCT04473963) is a prospective, multicenter, randomized clinical study in which patients with persistent or long-standing persistent AF who have failed prior PV isolation (PVI) undergo EGF mapping after confirmation of intact PVI. In total, 85 patients will be enrolled and stratified based on the presence or absence of EGF-identified sources. Patients with an EGF-identified source above the predetermined activity threshold of 26.5% will be randomized in a 1:1 fashion to PVI only vs PVI 1 ablation of EGF-identified extra-PV sources of AF.RESULTS The primary safety endpoint is freedom from serious adverse events related to the procedure through 7 days following the randomization procedure; and the primary effectiveness endpoint is the successful elimination of significant sources of exci-tation with the target parameter the activity of the leading source. CONCLUSIONS The FLOW-AF trial is a randomized study designed to evaluate the ability of the EGF mapping algorithm to identify pa-tients with active extra-PV AF sources.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Heart Rhythm O2
ISSN
2666-5018
e-ISSN
—
Volume of the periodical
4
Issue of the periodical within the volume
6
Country of publishing house
US - UNITED STATES
Number of pages
10
Pages from-to
391-400
UT code for WoS article
001032622100001
EID of the result in the Scopus database
2-s2.0-85162124228